Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. "Throughout my career, I have evaluated and seen many new drug candidates go from start to finish through the regulatory pathway and I am extremely optimistic and excited about the potential of Kevetrin? because of our data collected during extensive studies and the p53 connection as the Mechanism of Action. I'm not aware of any other anti-cancer compound at this stage of development that could have such a dramatic impact in the field of oncology.